DocMorris shares declined 1.7% on Wednesday after the Swiss pharmacy chain reported first-half revenue growth and narrowed its full-year loss guidance, while absorbing CHF 7.6 million in extraordinary costs tied to its AI strategy and facility closure.
The stock had surged more than 10% in pre-market trading on Tradegate following the release of stronger-than-expected second-quarter revenue in mid-July, but the gains reversed as investors digested the additional cost burden. DocMorris reported first-half external revenue growth of 12.5% in local currency, totaling CHF 627.8 million, alongside an adjusted EBITDA loss of CHF -10.9 million, a year-on-year improvement of CHF 17.9 million.
Management tightened its full-year adjusted EBITDA loss guidance to a range of CHF -10 million to CHF -17.5 million, compared with the prior outlook of up to CHF -25 million. The company indicated that progress toward EBITDA breakeven in the second half of 2026 remains achievable. One-off extraordinary charges of CHF 7.6 million were attributed to the implementation of the company’s AI-First strategy and the closure of its Ludwigshafen facility.
The market reaction reflected a classic "buy the rumor, sell the news" pattern, as DocMorris had already published a stronger-than-expected Q2 revenue update earlier in July. Peer Redcare Pharmacy advanced in sympathy with the guidance revision, while broader market conditions were neutral, with U.S. indices trading near flat and no Swiss-specific macro catalyst driving the session.
